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ABSTRACT
Premixes for medicated feedstuffs are considered to be veterinary medicinal products (VMPs) prepared 
in advance with a view to the subsequent manufacture of medicated feedstuffs. Medicated feedstuffs should 
be prepared only from market authorized premixes and premixes for medicated feedstuffs can be used only 
as prescribed medicines. Apart from active substances, premixes contain carriers which have a role in the 
homogenization of medicated feedstuffs. Wheat bran as a carrier may be a source of different, potentially 
harmful or toxic substances e.g. afl atoxin. In our study, 15 different batches of premixes with a wheat 
bran component were tested for afl atoxin B1 (AFB1) by means of an enzyme-linked immunosorbent assay 
(ELISA). The samples tested showed contamination with AFB1 ranging from 1.5 to 35 ng/g (mean = 18.79 
ng/g). However, no correlation between AFB1 levels and the month of collection or season of production was 
observed. Considering the composition of the premix, the only possible source of contamination with AFB1 
was wheat bran. Contamination probably occurred before the production of the premix, probably in the fi eld or 
during storage. Concentrations of active substances and citric acid (a neutralising agent for mycotoxins) were in 
accordance with the producer’s declaration. Our discovery of AFB1 in the tested premixes was in contravention 
of the defi nition and primary role of veterinary medicinal products. In this study, we would like to highlight 
the need for monitoring raw materials of biological origin for premix production. Even though carriers are 
not pharmacologically active substances, an effi cient method for controlling potential contaminants such as 
mycotoxins or their toxic components should be proposed, with the aim of protecting animal health, consumers, 
employees and end-users in the production of veterinary medicinal products. 
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Introduction
According to national and European legislation, premixes for medicated feedstuffs 
(any veterinary medicinal product prepared in advance with a view to the subsequent 
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manufacture of medicated feedstuffs) must be authorised (Directive 2001/82/EC). The 
majority of these veterinary medicinal products (VMPs) are used to treat food-producing 
animals and the quality control of such products is obligatory in Croatia. 
Apart from active substances, premixes contain carriers which allow the better 
homogenisation of medicated feedstuffs. An ideal carrier should be pharmaco-
toxicologically inactive, chemically and physically inert, compatible with other ingredients, 
colourless and tasteless, with high fl uidity or fl owability and high compressibility. It should 
be readily available and inexpensive, characterised in detail by suppliers (i.e. in a master 
fi le), easy to store, lot-to-lot reproducible and performance consistent, accompanied by a 
specifi c dosage form (PIFFERI et al., 1999). Commercially available authorised premixes 
in the Republic of Croatia contain different active substances (antibiotics, sulphonamides, 
coccidiostatics) and different carriers. Some of them contain carriers of natural (plant) 
origin. The most commonly used formulations of premixes include a grain carrier or 
mineral compound. 
The control of decomposition, specifi c impurities, chemical substances used during 
treatment, with residual limits and methods of sterilisation or decontamination of 
excipients, is necessary for the quality control of the VMP. The density, particle size and 
geometry of the premix should be similar to the feed with which it is intended to be mixed 
(VERMEULEN et al., 2002). Control of the purity and standard quality of carriers is also 
necessary. However, the quality of carriers may vary and depends on origins or storage 
conditions (FAZEKAS et al., 2005; SANTIN, 2005). 
Some authorised premixes contain wheat bran as a carrier that may be contaminated 
by different substances (pesticides, herbicides, mycotoxins etc.). The most frequent 
contaminant of feed or raw materials, including wheat bran, is AFB1. Afl atoxins are 
secondary metabolites produced by certain strains of the fungus Aspergillus. Well-known 
strains are Aspergillus fl avus, producing AFB1 and AFB2, and Aspergillus parasiticus 
producing AFB1, AFB2, AFG1 and AFG2 (DIENER and DAVIS, 1966). In addition, 
Aspergillus nominus and Aspergillus niger have also been described as producers of 
afl atoxins (HORN and WICKLOW, 1983). Contamination by afl atoxins is characteristic 
of humid tropical areas and is more frequently associated with storage under warm 
conditions than fi eld culture contamination. 68% of analysed feed samples produced in 
Southern Europe and 75% of feed samples from EU countries showed contamination by 
more than one mycotoxin (GRIESSLER et al., 2010; MONBALIU et al., 2010).
The toxicity of mycotoxins depends on the quantity, route of administration, exposure, 
animal species and category, genetics, age, rearing and interaction between mycotoxins 
(WYATT, 2005). The most prevalent and biologically active in animals and humans is 
afl atoxin (WILLIAMS et al., 2004; WILLIAMS et al., 2009). AFB1 belongs to the strongest 
naturally occurring liver carcinogens and is one of the most important afl atoxins, in terms 
of occurrence and toxicity (WOGAN, 1999). Many aspects of AFB1 toxicity both in human 
and animals have been investigated (KUILMAN et al., 2000; NURRED and RILEY, 2001; 
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OSWALD et al., 2005). Usually, animals are exposed to AFB1 in their diets and it can cause 
acute, chronic and subchronic mycotoxicoses. 
The aim of this study is to show that contamination of plant origin carriers with AFB1 
is possible. Our intention is to indicate the need for better quality control of raw materials 
or the replacement of non-standardised with standardised carriers, to protect animal and 
human health. We also want to point out the role of citric acid and the need for further 
study of its neutralising effect on AFB1 in animals.
Materials and methods
All the analyses were performed in the accredited (ISO 17025) laboratories 
(Laboratory for Quality Control of Veterinary Medicines and Laboratory for Analytical 
Chemistry) of the Croatian Veterinary Institute. 
Samples. Fifteen different batches of premixes with a wheat bran component, 
authorised primarily for the treatment of respiratory and digestive infections in young 
pigs, cattle and chickens, were tested for AFB1. The premixes were homogenously mixed 
in feed for pigs (0.5%) and feed for poultry (0.15-0.5%).
Samples for analysis were obtained through the routine quality control procedure 
that is mandatory in Croatia. The premixes were produced during a period of 28 months 
(September 2007 to December 2009) and stored under recommended conditions in 
aluminium bags until the moment of analysis. Three samples from the same batch were 
mixed and a sample of the mixture taken for analysis. 
Table 1. Composition of premix and proportion of wheat bran
No. of batches Active ingredients Wheat bran (%)
15
oxytetracycline as oxytetracycline hydrochloride, neomycin 
as neomycin sulphate, sulphadimidine, sulphaguanidine, 
citric acid
44.2
Sample preparations and analyses. The identifi cation and assay of active substances 
colour, homogeneity and loss of drying was assessed according to the producer’s quality 
control procedure. The method for determining the presence and level of citric acid has 
been described in European Pharmacopoiea 6th Ed. (01/2008:0455).
Representative samples were thoroughly mixed prior to extraction. Five grams of each 
sample was weighed, and then 25 mL of 70% methanol was added and the mixture shaken 
vigorously for three minutes. The extract was fi ltrated and 1 mL of the obtained fi ltrate 
was diluted with 1 mL of distilled water. Aliquots (50 μL) of dilutions were assayed in 
duplicate by ELISA. Competitive ELISA was performed as described in the instructions 
provided by the kit manufacturer.
158 Vet. arhiv 82 (2), 155-166, 2012
S. Terzić et al.: Afl atoxin B1 in wheat bran containing premix
A Ridascreen AFB1 kit for ELISA was provided by R-Biopharm (Darmstadt, 
Germany). Each kit contains a microtiter plate with 96 wells coated with capture antibodies, 
AFB1 standard solutions (0, 1, 5, 10, 20 and 50 ng/mL), peroxidase-conjugated AFB1, 
anti-afl atoxin antibody, substrate/chromogen, stop solution (1 N sulphuric acid) and 
washing buffer (contains 0.05% Tween 20). AFB1 from Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) was used for the fortifi cation of samples. All other chemicals used 
in the analysis were of analytical grade. ELISA was performed by using ChemWell 2910 
(Awareness Technology, USA). 
Results
Validation. The estimated limit of detection (LOD) and limit of quantifi cation (LOQ), 
which was calculated from the mean value of ten determinations of blank samples of 
different cereals, plus three- and ten-fold standard deviations, were 1.0 and 1.6 ng/g, 
respectively. The results of method recovery (n = 18) and repeatability (n = 54) are 
presented in Table 2. 
Table 2. Results of method validation obtained with blank samples of different cereals spiked with 

















6 2 1.85 92.5 7.7
6 10 10.15 101.5 9.3
6 20 19.34 96.7 10.2
Repeatability
18 2 1.73 86.5 9.7
18 10 10.46 104.6 10.6
18 20 18.86 94.3 11.5
Method validation resulted in mean recoveries ranging from 92.5% to 101.5% and 
repeatability ranging from 86.5% to 104.6%, with coeffi cients of variations (CV) of 
7.7%-10.2% and 9.7%-11.5% respectively. 
Qualitative analyses and occurrence of AFB1. The quantity and identifi cation of active 
substances was in accordance with the producer’s specifi cation (certifi cate of quality) as 
well as other requirements in all of the samples assessed. The quantity of AFB1 in the 
premixes analysed is shown in Table 3.
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Fig. 1. ELISA standard curve for afl atoxin B1
Table 3. Concentration of AFB1 (ng/g) in analysed premixes and descriptive statistics of results.

















Standard error 2.49 0.71
Median 18.3 96.1
Standard deviation 9.67 2.76
Concentrations of citric acid were in accordance with the producer’s specifi cation in 
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Discussion
The safety of veterinary medicinal products is a very important part of preclinical 
investigation, evaluation of documentation, and the post marketing authorisation process. 
Animals, the environment, and people who apply or are exposed to veterinary medicinal 
products, should be protected from any harmful effects (WOODWARD, 2008). Apart 
from active substances, the safety and toxicity of excipients play an important role in 
medicinal products (BALDRICK, 2000; de JONG, 1999; OSTERBERG and SEE, 2003). 
Excipients account for most of the volume of veterinary medicinal products and must also 
correspond to safety requirements (PIFFERI and RESTANI, 2003). The carriers in premixes 
are edible materials to which drugs have been added to facilitate uniform incorporation 
in feedstuffs. However, the criteria which have been proposed for the quality control of 
different kinds of carriers in veterinary medicinal products are unsatisfactory. 
The origin of raw materials and well established use of veterinary medicines are not 
a guarantee of quality as required by the pharmaceutical industry (PIFFERI and RESTANI, 
2003). After considering our fi ndings, we agree with LONG and CRANE (2003) that the 
harmonisation of veterinary medicine regulation is an ongoing process and requirements 
for carriers should be improved continually. 
There is limited information on veterinary medicines that contain wheat bran. Wheat 
bran can be a source of Aspergillus spp. and mycotoxins. The contamination of wheat 
bran with afl atoxin is possible in the fi eld, during storage, or in the manufacturing process. 
Requirements for wheat bran quality fall under legislation for feed, although wheat bran 
can also be an ingredient of veterinary medicinal products. There is no national legislation 
regarding the quantity of AFB1 in wheat bran as a carrier in veterinary medicinal products. 
However, the maximum level of AFB1 is 0.02 ng/g in complete feed for cattle, goats and 
sheep, except milk producing animals (0.005 ng/g) and (0.01 ng/g) in feedstuff for calves 
and lambs. The maximum content of AFB1 in feedstuff for pigs and poultry is 0.02 ng/g, 
except for young animals (0.01 ng/g). The maximum concentration of afl atoxin in food in 
Croatia, as in the majority of European countries, must not exceed 5 ng/g.
ELZUPIR et al. (2003) reported that 63% of wheat bran samples analysed were positive 
for afl atoxin (average 31.19 μg/kg) in Sudan and BARA (2008) found that the concentration 
of afl atoxin in bran varied from 0.0 to 0.27 ppm (an average of 0.09 ppm). Rice and rice 
hulls also presented a risk of afl atoxin contamination (CASTELLS et al., 2007). 
The harmful effects of afl atoxin on animal health have been described in many studies. 
Afl atoxin can cause stunted growth in lambs and provoke the selective impairment of drug-
metabolizing enzymes in pig livers (FERNANDEZ et al., 1997; FERNANDEZ et al., 2000; 
GOWDA et al., 2007; MEISSONNIER et al., 2007). The immunosuppressant effect of many 
mycotoxins occurs at much lower levels of intake than the toxins affecting production 
parameters, such as growth rate or egg production (BONDY and PESTKA, 2000). Pigs are 
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very susceptible to afl atoxin, especially young pigs, and AFB1 dietary exposure decreases 
cell mediated immunity, while inducing an infl ammatory response (MEISSONNIER et al., 
2008). Toxin ingestion can also reduce the effectiveness of vaccines (MEISSONNIER et 
al., 2006; MEISSONNIER et al., 2008). Even though piglets are most susceptible to AFB1, 
50 μg/kg of feed does not have a toxic effect (DILKIN et al., 2003). However, the same 
authors reported the negative effects on feed consumption and feed conversion in pigs 
that received a combination of AFB1 (50 μg/kg) and 30 mg fumonisin B1 (FB1) over a 
period of four weeks. 
Mixing AFB1 and FB1 was assessed by THEUMER et al. (2003) too, and it was found 
that such mixtures of mycotoxins caused severe changes to the immunological system 
in rats. BARA (2008) reported the negative effect of afl atoxin in feedstuffs on poultry 
production and OGUZ et al. (2002) observed that hepatic enzyme activities (AST and ALT) 
signifi cantly increased in one-day old broiler chickens, after being fed (for 42 days) a diet 
containing 50 and 100 ng/g of AFB1.
The immunosuppressive effects of AFB1 in fi sh have also been recorded (SAHOO 
and MUKHERJEE, 2001). EL-SAYED and KHALIL (2009) found that sea bass were highly 
sensitive to AFB1 and the consumption of sea bass reared on an AFB1 contaminated diet 
could have a negative impact on human health. 
Five out of twenty authorised premixes for commercial use in Croatia contain wheat 
bran in different proportions (from 442 to 980 g/kg). During routine control, the non-
appropriate appearance of some batches of premixes was observed and we decided to 
analyse premix samples for the presence of AFB1, even though the control of mycotoxins 
and side contaminants in premixes was not covered in the producers’ documentation. In 
our study, the premixes tested showed a concentration of AFB1of between 1.5 and 35 ng/g 
(mean = 18.79, standard error = 2.49). Considering the composition of the premixes, the 
only possible source of AFB1 contamination was wheat bran. Validation results showed 
that the method of sample preparation and determination of AFB1 using ELISA as a 
screening method for quantitative determination was effi cient and comparable with the 
manufacturer’s data. Based on the composition of VMP, we assumed that the source of 
afl atoxins was wheat bran. 
However, there was no correlation between AFB1 levels and the date of the premix 
production. Since the premixes were packed in different packaging materials (aluminium 
bags, paper bags and PVC bags) we presume the packaging had no infl uence on the AFB1 
concentration. Contamination probably occurred before premix production, probably in 
the fi eld or during the storage of wheat bran. 
The concentration of AFB1 found in premix decreases in the fi nal composition of 
medicated feedstuffs, since 0.5 kg of premix is added to 100 kg of feed. Therefore the 
fi nal concentration of afl atoxin is lower than 5 ng/g, i.e. within the permitted level of 
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concentration for young animals (0.005 ng/g). However, the presence of a certain 
quantity of afl atoxins or other mycotoxins may also be found in feed and the combined 
concentration is in that case higher. The toxic effect of AFB1 depends not only on its 
total quantity, but on the animal’s length of exposure, species, physiological status, age, 
sex etc. (HENGSTLER et al., 1999). Low levels of mycotoxins favour the development of 
infectious diseases through impairment of the humoral and cellular immune response and 
native mechanisms of resistance. In general, AFB1 should not be present in veterinary 
medicinal products at any level of concentration. 
In our investigation, we recorded that premixes also contain citric acid (100 g/kg). 
The results show small divergences within the specifi cation indicated for standardised 
production. In the instructions for use, the manufacturer states that citric acid is used 
as an acidifi er to reduce E. coli and anaerobic bacteria in the digestive system, not as a 
detoxifi cation agent. However, citric acid has been proved to have a detoxifying effect 
regarding AFB1 in broilers (GOWDA et al., 2004). Citric acid in 0.5-1% concentration is 
a very effective anti-fungal compound and it reduces (91-94%) afl atoxin biosynthesis 
by A. parasiticus. 1 N aqueous citric acid signifi cantly prevented negative effects on 
body weight gain and transaminase activity in young ducks given feed contaminated with 
110 ng/g AFB1 (MENDEZ-ALBORES et al., 2007). Sorghum contaminated with AFB1 can 
also be detoxifi ed by citric aqueous acid during the extrusion process, without affecting 
the physicochemical, functional and textural properties of the extrudates (MENDEZ-
ALBORES et al., 2009). Hot air ovens and sun drying reduces afl atoxin content in feed, and 
some chemical and herbal compounds have an anti-fungal effect, so they can also reduce 
afl atoxin production (GOWDA et al., 2007). The inhibition of Aspergilus parasiticus growth 
and afl atoxin production has been achieved through the use of propionic acid, ammonia, 
copper sulphate, benzoic acid urea, citric acid and sodium propionate acid (GOWDA et 
al., 2004). High dietary vitamin C enhanced protection against Aeromonas hydrophila 
infection in both healthy and AFB1 immunocompromised fi sh (SAHOO and MUKHERJEE, 
2001). Usually, chemical detoxifi cation is not completely safe, due to toxic residues. 
Treatment with sodium bisulphite and ammoniation is successful in the inactivation 
of afl atoxin in peanut meals, maize and cottonseed while fungal laccase enzymes are 
effi cacious in the degradation of AFB1 (ALBERTS et al., 2009; MENDEZ-ALBORES et al., 
2007). In our study, the concentration of citric acid was within the declared range. In 
accordance with previous studies carried out by many authors, we can only assume that 
small quantities of AFB1 in the premixes analysed may be neutralised by citric acid in 
the proposed concentration in the digestive systems of animals. However, we consider 
that AFB1 should not even be present in premixes and we consider that the control of raw 
materials for premix production, both active substances and excipients, should be clearly 
prescribed, according to good manufacturing practice. Non-standardised carriers in the 
veterinary pharmaceutical industry may be the sources of potentially harmful or toxic 
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substances. This contravenes the primary defi nition of veterinary medicinal products, in 
terms of their safety. Even though the carrier may not be a pharmacologically active 
substance, measures are necessary to minimise the undesired effects caused by some 
extraneous substances. 
In conclusion, contamination with AFB1 can be prevented by routine control of the 
plant material components of premixes. Citric acid, which was found to be a component 
of the samples investigated, can help to neutralise AFB1 in premixes. 
Our study was based on fi nished, authorised products, however, for further 
investigation, studies should be extended to raw materials and clinical trials (investigation 
of the toxic effects of low concentrations of AFB1 as well as the neutralisation of AFB1 with 
citric acid in animals). Therefore, we consider that this study highlights the absence of 
control regarding the raw materials for premix production, especially those of biological 
origin.
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SAŽETAK
Premiksi za izradu ljekovite hrane za životinje svrstani su u veterinarsko-medicinske proizvode (VMP). 
Ljekovita hrana mora biti propisana od veterinara i može se pripremati samo od premiksa koji imaju odobrenje 
za stavljanje u promet. Osim aktivnih tvari, premiksi sadržavaju i nosače koji omogućavaju njihovo bolje 
umješavanje u hranu za životinje. Pšenične posije kao nosač aktivnih tvari mogu biti potencijalni izvor različitih 
opasnih ili toksičnih tvari kao što je npr. afl atoksin. U našem istraživanju imunoenzimnim testom (ELISA) 
analizirano je 15 različitih proizvodnih serija premiksa za izradu ljekovite hrane za životinje na afl atoksin B1 
(AFB1). Testirani uzorci imali su od 1,5 do 35 ng/g (M = 19,79 ng/g) AFB1. Međutim u našem istraživanju 
nije ustanovljena povezanost količine AFB1 s godišnjim dobom proizvodnje. S obzirom na sastav premiksa 
vjerojatno su pšenične posije izvor kontaminacije, a kontaminacija je nastala vjerojatno prije proizvodnje 
premiksa, odnosno prije ili tijekom skladištenja pšeničnih posija. Količina aktivnih tvari i limunske kiseline 
koja je potencijalni neutralizator AFB1 odgovarala je deklaraciji proizvođača. Nalaz potencijalno štetnih tvari 
(AFB1) u VMP-u u suprotnosti je s ulogom veterinarskog lijeka te se ovim istraživanjem željelo upozoriti na 
izostanak kontrole sirovina biološkog podrijetla u proizvodnji premiksa. Iako nosači nisu farmakološki aktivne 
tvari, kontrola kontaminanata kao što su mikotoksini ili druge toksične tvari trebala bi se povećati u cilju zaštite 
zdravlja životinja i ljudi (potrošača, osoba koje rukuju premiksima i sirovinama).
Ključne riječi: premiks, afl atoksin B1, pšenične posije ________________________________________________________________________________________
